Steward Partners Investment Advisory LLC Raises Stock Position in Doximity, Inc. (NASDAQ:DOCS)

Steward Partners Investment Advisory LLC increased its stake in Doximity, Inc. (NASDAQ:DOCS) by 17.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,269 shares of the company’s stock after acquiring an additional 332 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Doximity were worth $121,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DOCS. Plato Investment Management Ltd purchased a new stake in shares of Doximity during the fourth quarter worth $207,000. SBI Securities Co. Ltd. purchased a new stake in shares of Doximity during the fourth quarter worth $4,207,000. West Michigan Advisors LLC purchased a new stake in shares of Doximity during the fourth quarter worth $306,000. US Bancorp DE grew its holdings in shares of Doximity by 7.8% during the fourth quarter. US Bancorp DE now owns 11,285 shares of the company’s stock worth $603,000 after buying an additional 818 shares in the last quarter. Finally, Fielder Capital Group LLC grew its holdings in shares of Doximity by 4.5% during the fourth quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock worth $293,000 after buying an additional 235 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DOCS shares. Raymond James reaffirmed an “outperform” rating and set a $83.00 target price (up previously from $65.00) on shares of Doximity in a report on Friday, February 7th. Stephens started coverage on shares of Doximity in a report on Friday, December 20th. They set an “equal weight” rating and a $55.00 target price for the company. Canaccord Genuity Group upped their price objective on shares of Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a report on Friday, February 7th. Leerink Partnrs raised shares of Doximity from a “hold” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Leerink Partners raised shares of Doximity from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $60.00 to $90.00 in a report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Doximity presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.22.

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 37.40% of the company’s stock.

Doximity Price Performance

NASDAQ DOCS opened at $63.33 on Monday. The stock has a market capitalization of $11.82 billion, a P/E ratio of 63.33, a PEG ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The firm’s 50-day moving average is $63.63 and its two-hundred day moving average is $52.72.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.